312 related articles for article (PubMed ID: 25703120)
1. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.
Gisbert JP; Romano M; Gravina AG; Solís-Muñoz P; Bermejo F; Molina-Infante J; Castro-Fernández M; Ortuño J; Lucendo AJ; Herranz M; Modolell I; Del Castillo F; Gómez J; Barrio J; Velayos B; Gómez B; Domínguez JL; Miranda A; Martorano M; Algaba A; Pabón M; Angueira T; Fernández-Salazar L; Federico A; Marín AC; McNicholl AG
Aliment Pharmacol Ther; 2015 Apr; 41(8):768-75. PubMed ID: 25703120
[TBL] [Abstract][Full Text] [Related]
2. Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management.
Pabón-Carrasco M; Keco-Huerga A; Castro-Fernández M; Saracino IM; Fiorini G; Vaira D; Pérez-Aísa Á; Tepes B; Jonaitis L; Voynovan I; Lucendo AJ; Lanas Á; Martínez-Domínguez SJ; Almajano EA; Rodrigo L; Vologzanina L; Brglez Jurecic N; Denkovski M; Bujanda L; Abdulkhakov RA; Huguet JM; Fernández-Salazar L; Alcaide N; Velayos B; Silkanovna Sarsenbaeva A; Zaytsev O; Ilchishina T; Barrio J; Bakulin I; Perona M; Alekseenko S; Romano M; Gravina AG; Núñez Ó; Gómez Rodríguez BJ; Ledro-Cano D; Pellicano R; Bogomolov P; Domínguez-Cajal M; Almela P; Gomez-Camarero J; Bordin DS; Gasbarrini A; Kupčinskas J; Cano-Català A; Moreira L; Nyssen OP; Mégraud F; O'Morain C; Gisbert JP;
United European Gastroenterol J; 2024 Feb; 12(1):122-138. PubMed ID: 38050339
[TBL] [Abstract][Full Text] [Related]
3. Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial.
Zhang D; Ke L; Ni Z; Chen Y; Zhang LH; Zhu SH; Li CJ; Shang L; Liang J; Shi YQ
Medicine (Baltimore); 2017 Aug; 96(32):e7697. PubMed ID: 28796053
[TBL] [Abstract][Full Text] [Related]
4. 14-day tailored PCR-guided triple therapy versus 14-day non-Bismuth concomitant quadruple therapy for Helicobacter pylori eradication: A multicenter, open-label randomized noninferiority controlled trial.
Amiot A; Hacoon J; Heluwaert F; Mion F; Lamarque D; Moussata D; Mimouni M; Delchier JC; Durand-Zaleski I; Audureau E; Bastuji-Garin S;
Helicobacter; 2024; 29(2):e13076. PubMed ID: 38680067
[TBL] [Abstract][Full Text] [Related]
5. Fourteen-day vonoprazan-based bismuth quadruple therapy for H. pylori eradication in an area with high clarithromycin and levofloxacin resistance: a prospective randomized study (VQ-HP trial).
Tungtrongchitr N; Bongkotvirawan P; Ratana-Amornpin S; Siramolpiwat S; Eiamsitrakoon T; Gamnarai P; Wongcha-Um A; Yamaoka Y; Pawa KK; Vilaichone RK
Sci Rep; 2024 Apr; 14(1):8986. PubMed ID: 38637591
[TBL] [Abstract][Full Text] [Related]
6. Second-line bismuth-containing quadruple therapy for
Kim SE; Park MI; Park SJ; Moon W; Kim JH; Jung K; Kim HK; Lee YD
World J Gastroenterol; 2017 Feb; 23(6):1059-1066. PubMed ID: 28246480
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Tetracycline Three Times Daily was Comparable to That of Four Times Daily for Helicobacter pylori Rescue Treatment: A Multicenter, Noninferiority, Randomized Controlled Trial.
Han Z; Zhang Q; Mirza IA; Ding Y; Nan X; Zhao Q; Li R; Xu L; Zhang N; Duan M; Zeng S; Kong Q; Zhang W; Wang H; Wu X; Zuo X; Li Y; Li Y
Helicobacter; 2024; 29(3):e13102. PubMed ID: 38873902
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of levofloxacin, amoxicillin and a proton pump inhibitor in the eradication of Helicobacter pylori in Brazilian patients with peptic ulcers.
Silva FM; Queiroz EC; Navarro-Rodriguez T; Barbuti RC; Mattar R; Iriya K; Lee JH; Eisig JN
Clinics (Sao Paulo); 2015 May; 70(5):318-21. PubMed ID: 26039946
[TBL] [Abstract][Full Text] [Related]
9. Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori.
Cheng H; Hu FL
World J Gastroenterol; 2009 Feb; 15(7):860-4. PubMed ID: 19230048
[TBL] [Abstract][Full Text] [Related]
10. Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial.
Kim YI; Lee JY; Kim CG; Park B; Park JY; Choi IJ
BMC Gastroenterol; 2021 Mar; 21(1):95. PubMed ID: 33653284
[TBL] [Abstract][Full Text] [Related]
11. Ten-Day Vonoprazan-Amoxicillin Dual Therapy vs Standard 14-Day Bismuth-Based Quadruple Therapy for First-Line Helicobacter pylori Eradication: A Multicenter Randomized Clinical Trial.
Yan TL; Wang JH; He XJ; Zhu YB; Lu LJ; Wang YJ; Wang ZW; Gao JG; Xu CF; Ma H; Luan SM; Li L; Chen Y
Am J Gastroenterol; 2024 Apr; 119(4):655-661. PubMed ID: 37975609
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Efficacy of 12-day Concomitant Quadruple Therapy versus 14-day High dose Dual Therapy as a First-line
Valizadeh Toosi SM; Feyzi S; Kazemi A
Korean J Gastroenterol; 2024 Apr; 83(4):150-156. PubMed ID: 38659251
[TBL] [Abstract][Full Text] [Related]
13. A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: A single center experience.
Abd-Elsalam S; Kobtan A; El-Kalla F; Elkhalawany W; Nawasany SE; Saif SA; Yousef M; Ali LA; Soliman S; Mansour L; Habba E; Soliman H; Rizk F; Shehata MA
Medicine (Baltimore); 2016 Jun; 95(24):e3879. PubMed ID: 27310977
[TBL] [Abstract][Full Text] [Related]
14. Fourteen-Day Tegoprazan-Amoxicillin Dual Therapy as the First-Line Treatment of Helicobacter pylori Infection (SHARE2301): A Multicenter, Noninferiority, Randomized Clinical Trial.
Kong Q; Mirza IA; Zhang X; Song X; Li X; Zhang Q; Xu L; Guo Y; Yu Y; Zuo X; Li Y; Li Y
Helicobacter; 2024; 29(3):e13098. PubMed ID: 38853394
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis.
Li BZ; Threapleton DE; Wang JY; Xu JM; Yuan JQ; Zhang C; Li P; Ye QL; Guo B; Mao C; Ye DQ
BMJ; 2015 Aug; 351():h4052. PubMed ID: 26290044
[TBL] [Abstract][Full Text] [Related]
16. Randomised clinical trial: comparison of efficacy and adverse effects of a standard triple clarithromycin-containing regimen with high-dose amoxicillin and bismuth therapy in Helicobacter pylori eradication.
Sjomina O; Lielause A; Rūdule A; Vangravs R; Paršutins S; Poļaka I; Daugule I; Stonāns I; Park JY; Leja M
Eur J Cancer Prev; 2022 Jul; 31(4):333-338. PubMed ID: 35471812
[TBL] [Abstract][Full Text] [Related]
17. Application of a semi-automatic, intensive follow-up for improving efficacy and adherence of Helicobacter pylori eradication therapy: A randomized controlled trial.
Chen Y; Yuan H; Ye H; Shi Z; Deng X; Zhang X; Hou X
Microbiologyopen; 2021 Jan; 10(1):e1172. PubMed ID: 33650799
[TBL] [Abstract][Full Text] [Related]
18. High-dose dual therapy versus bismuth-containing quadruple therapy for the eradication of Helicobacter pylori: A systematic review and meta-analysis.
Wang H; Kong QZ; Li YY; Yang XY; Zuo XL
J Dig Dis; 2024 Mar; 25(3):163-175. PubMed ID: 38577962
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Helicobacter pylori infection: current status and future concepts.
Yang JC; Lu CW; Lin CJ
World J Gastroenterol; 2014 May; 20(18):5283-93. PubMed ID: 24833858
[TBL] [Abstract][Full Text] [Related]
20. Single-capsule bismuth quadruple therapy: preferable at the moment, but what should be next?
Suzuki H; Mori H
United European Gastroenterol J; 2021 Feb; 9(1):7-8. PubMed ID: 33210981
[No Abstract] [Full Text] [Related]
[Next] [New Search]
